A user is considering using verteporfin with microneedling, oral/topical minoxidil, and RU58841 to treat hair loss. They seek advice on dosage and application methods.
A 25-year-old is using vinpocetine to enhance the absorption of topical Minoxidil for hair loss. They also use a hair tonic and supplement with Glycine, Taurine, Creatine, and Citrulline.
Veradermics is a promising new treatment for hair loss, essentially a repackaged version of Minoxidil. The user is optimistic about its potential effectiveness.
Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.
A new Latanoprost-based formula used by Hollywood celebrities to treat hair loss, with the formula containing minoxidil, tretinoin, melatonin, azelaic acid, zinc thymulin, vitamin B6, sandalore and methyl vanillate. It also mentions the potential of offering a combined sublingual minoxidil/oral dutasteride option in the future.
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.
Testing the effectiveness of Verteporfin as a potential treatment for hair loss, with users discussing their thoughts on its long-term results. Treatments mentioned include Minoxidil, Finasteride, and RU58841.
The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.
VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.
Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.
Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.
Vitamin E is suggested as beneficial for hair follicles. Some users question the dosage and effectiveness, while others share positive experiences with vitamins.
Using Vitamin C serum after dermarolling may help with healing and hair health. The safety of additional ingredients like Glycerin, Propylene Glycol, Phenoxyethanol, Sodium Benzoate, and Sodium Metabisulfite in hair regrowth is questioned.
Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.
The conversation is about a hair loss regimen using Veta hair products, 2% keto shampoo, 1% zinc shampoo, and 0.05% retin-a topical. The user seeks natural alternatives due to adverse effects from finasteride.
L'Oreal Serioxyl and Garnier Fructus Stemoxydine are compared for effectiveness in hair loss treatment. The user considers switching from Serioxyl to the cheaper Garnier Fructus but is unsure about its effectiveness and stemoxydine percentage.
The conversation is about recommending a biotin supplement that includes saw palmetto and possibly copper for hair loss. The user is seeking suggestions for these specific ingredients.
Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.
A dermatologist recommended a new supplement containing annurca apple, which reportedly doubles hair density and increases keratin after 60 days, to be used with finasteride. Some users are skeptical, considering it potentially ineffective or a marketing ploy, while others are open to trying it if it proves effective and affordable.
The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.
The conversation is about making topical finasteride using stemoxydine as a carrier. The user is considering buying Redken Cerafill Hair Re-Densifying Treatment (Stemoxydine) 90ml for this purpose.
Capilia Longa is considered as an alternative to Minoxidil for beard growth, with some users reporting positive results. However, concerns exist about its effectiveness and high cost, especially for scalp use.
Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.
A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.
The conversation discusses the effectiveness of a multivitamin containing Zinc, Biotin, B12, B6, B2, B1, Vitamin D, and Iron for hair loss. The multivitamin is from a reliable but inexpensive brand in Brazil.
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.